Compare Oscar Health Inc (OSCR) vs Ferrari NV (RACE) Price & Performance

OSCR trades at $33.37, up 1.4% with strong technical momentum and bullish moving averages. The company shows impressive revenue growth from $11.7B in 2025 to $15.3B in 2026, turning profitable with $551M net income. Recent Q1 and Q2 2026 earnings beat expectations, while analyst consensus leans toward Hold (61.54%) with a $34 price target. Technical indicators show bullish signals but RSI suggests potential overbought conditions near-term.

Outlook remains positive with scalable ACA market growth and margin expansion driving earnings potential. Key risks include rising medical costs threatening profitability and competitive pressures. The stock offers growth exposure but requires monitoring of execution on 2029 EPS targets of $4+ and medical loss ratio management.

Ferrari (RACE) trades at $389.91, up 0.91% today, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue and net income have grown steadily, reaching $7.15B and $1.60B in 2025, respectively. The company maintains high profitability margins and a robust balance sheet, though cash flow trends show recent volatility. Recent news highlights a share buyback program and strategic partnerships, supporting investor confidence.

The outlook for Ferrari remains positive due to consistent earnings beats, high margins, and analyst optimism, with a consensus price target of $462.75 implying 18.7% upside. Risks include valuation multiples above industry averages, competitive pressures in the luxury automotive sector, and macroeconomic sensitivity. Institutional buying activity and a dominant buy rating from analysts underscore long-term growth potential, but investors should monitor execution on future earnings and market sentiment shifts.